From the Service d'Hématologie—Greffe de Moelle, "Trèfle 3," Hôpital Saint Louis, Paris, France; Etablissement Français du Sang, Hôpital Saint Louis, Paris, France; and Laboratoire de Pathologie ERM 02 20 INSERM, Université de Paris VII, Paris, France.
To assess whether Fanconi anemia (FA) patients might be at risk for acute graft-versus-host disease (AGvHD) despite using low-intensity conditionings, we retrospectively analyzed the incidence of AGvHD and its impact on outcome in 37 FA patients and 73 patients with acquired aplastic anemia (AAA) that received transplants at Saint Louis Hospital from HLA-genotypic identical siblings with similar conditionings (thoraco-abdominal irradiation plus cyclophosphamide 20 [FA] or 150 mg/kg [AAA]). Despite being younger, FA patients had an increased risk of grades II to IV AGvHD (relative risk [RR], 2.00; P = .021), especially in younger patients (RR, 7.93; P = .014). The risks of requiring systemic corticosteroids to treat AGvHD and experiencing cortico-resistant AGvHD were significantly increased in FA patients. Although non-FA and FA patients had similar 10-year outcomes, acute and chronic GvHD had a biphasic effect on FA patient outcome with an additional cluster of lethal events starting by 5 years after transplantation. This late survival fall, restricted to FA patients, was closely related to head and neck carcinomas (15-year incidence: 53%). FA patients represent a group at risk regarding AGvHD when using irradiation-based conditionings. The impact of AGvHD on survival may not be limited to the early posttransplantation period and may be a major risk factor for head and neck carcinomas and late mortality in FA patients.
Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Fran?aise de Greffe de Mo?lle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and Int
Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation
In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets
Critical role of host T cells in experimental acute graft-versus-host disease
CCR6 regulates CD4+ T-cell–mediated acute graft-versus-host disease responses
emergent autoimmunity in graft-versus-host disease
Leukocyte migration and graft-versus-host disease
New approaches for preventing and treating chronic graft-versus-host disease
Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM)
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission